Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Flexner

Showing results (31-40 of 137) with videos related to

Pageof 14
Sort By:
The Journal of Infectious Diseases|August 21, 2008
Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countriesKelly E Dooley, Charles Flexner, Adriana S Andrade
Annals of the Academy of Medicine, Singapore|January 11, 2013
Unexpected drug-drug interactions in human immunodeficiency virus (HIV) therapy: induction of UGT1A1 and bile efflux transporters by EfavirenzLawrence S U Lee, Paul Pham, Charles Flexner
Antiviral Therapy|October 14, 2014
Simplification of antiretroviral therapy: a necessary step in the public health response to HIV/AIDS in resource-limited settingsMarco Vitoria, Nathan Ford, Meg Doherty, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2022
The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious DiseasesCharles Flexner, Marco Siccardi, Fazila Bunglawala, et al.
Journal of the International AIDS Society|July 13, 2023
Advancing use of long-acting and extended delivery HIV prevention and treatment regimensSinéad Delany-Moretlwe, Charles Flexner, José A Bauermeister
Current Opinion in HIV and AIDS|October 9, 2013
Treatment optimization: an outline for future successCharles Flexner, Ben Plumley, David H Brown Ripin
Journal of Clinical Pharmacology|June 1, 2026
The High Cost of Inexpensive MedicinesGeorge Selali Blewusi, Ruohui Zheng, Lobna Gaayeb, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2022
What Clinicians Need to Know About the Development of Long-Acting FormulationsCharles Flexner, David L Thomas, Polly Clayden, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 20, 2006
Interactions between natural health products and antiretroviral drugs: pharmacokinetic and pharmacodynamic effectsLawrence S Lee, Adriana S A Andrade, Charles Flexner
The Journal of Infectious Diseases|July 23, 2002
Differential effects of p-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infectionR Renae Speck, Xiao-Fang Yu, James Hildreth, et al.
Pageof 14

Showing results (31-40 of 137) with videos related to

Sort By:
Pageof 14
The Journal of Infectious Diseases|August 21, 2008
Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countriesKelly E Dooley, Charles Flexner, Adriana S Andrade
Annals of the Academy of Medicine, Singapore|January 11, 2013
Unexpected drug-drug interactions in human immunodeficiency virus (HIV) therapy: induction of UGT1A1 and bile efflux transporters by EfavirenzLawrence S U Lee, Paul Pham, Charles Flexner
Antiviral Therapy|October 14, 2014
Simplification of antiretroviral therapy: a necessary step in the public health response to HIV/AIDS in resource-limited settingsMarco Vitoria, Nathan Ford, Meg Doherty, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2022
The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious DiseasesCharles Flexner, Marco Siccardi, Fazila Bunglawala, et al.
Journal of the International AIDS Society|July 13, 2023
Advancing use of long-acting and extended delivery HIV prevention and treatment regimensSinéad Delany-Moretlwe, Charles Flexner, José A Bauermeister
Current Opinion in HIV and AIDS|October 9, 2013
Treatment optimization: an outline for future successCharles Flexner, Ben Plumley, David H Brown Ripin
Journal of Clinical Pharmacology|June 1, 2026
The High Cost of Inexpensive MedicinesGeorge Selali Blewusi, Ruohui Zheng, Lobna Gaayeb, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2022
What Clinicians Need to Know About the Development of Long-Acting FormulationsCharles Flexner, David L Thomas, Polly Clayden, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 20, 2006
Interactions between natural health products and antiretroviral drugs: pharmacokinetic and pharmacodynamic effectsLawrence S Lee, Adriana S A Andrade, Charles Flexner
The Journal of Infectious Diseases|July 23, 2002
Differential effects of p-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infectionR Renae Speck, Xiao-Fang Yu, James Hildreth, et al.
Pageof 14